The size of the Bioreactors Market in the Asia Pacific was valued at USD 201.24 Million in 2022. This value is estimated to be growing at a CAGR of 8.12% to reach USD 297.34 Million by 2027 during the forecast period.
Rising Chronic disease prevalence and increasing biopharmaceutical investments will propel the growth of the market. Bioreactors are complexly designed manufacturing devices that sustain a biologically active environment. Production or Manufacture of vaccines, enzymes, and other substances is done by a chemical process that involves organisms or biologically active derivatives extracted from organisms. Bioreactors are used for manufacturing these substances and have endless applications in many fields like tissue engineering, Biochemical Engineering, etc.
The main drivers contributing to the market's growth are rising biopharmaceutical investments, increasing demand for therapeutically active vaccines, increasing chronic disease prevalence, an increase in the incidence of lifestyle diseases like diabetes and cancer, product innovation, and favorable government initiatives to develop healthcare infrastructure. Growing personalized medicine market and increasing popularity for them and increasing the popularity of single-use bioreactors among the biopharmaceutical companies will also aid in the market's growth.
But, regulatory issues regarding single-use bioreactors, limited storage, and vulnerability to leaching may hinder the market's growth. Also, large-scale disposal of plastic derivatives is an environmental concern restraining growth.
This research report on the APAC Bioreactors Market has been segmented and sub-segmented the North America Bioreactors Market into the following categories:
By Production Size:
By Control Type:
By End Users:
Geographically, the APAC bioreactors market is projected to grow with a noticeable growth rate during the forecast period due to the growing prevalence of diseases such as diabetes, cancer, and other chronic diseases. Growing biopharmaceutical and investments with rising contract manufacturing organizations are further estimated to add fuel to the market growth in this region. Countries like China and India have shown lucrative growth in this region in the past years. Moreover, colossal expenditure is approved for the manufacturing of biologics.
The Indian bioreactors market is predicted to a considerable growth rate of 19.8% during the analysis period due to the growing technological acquisition, rising healthcare expenditure, which surges the growth. Increasing product invention and favorable government measures in developing the healthcare infrastructure, which will swell the growth. Huge demand in the biopharmaceutical industry, concentrated research and development efforts foster the market.
The Chinese bioreactors market is expected to lead the market with advanced technologies considered with different single-use bioreactors, which augment this region's growth. Growing demand for personalized medicine with an integrated familiarity of single-use bioreactors in different biopharmaceutical companies will accelerate the APAC region's growth.
Japan is expected to record the bioreactors market size of USD 40.7 million in 2018 in terms of revenue. The growth is caused by increasing economic support from the government for enhancing new drugs and a growing number of biopharmaceutical companies in this region. Increasing aging population and growing healthcare standards and expenditure, growing approvals for biologics may also foster the growth.
Moreover, in countries like South Korea, the Philippines, Malaysia, Singapore, and India, to get rid of diseases, preventive measures have been taken.
Notable companies dominating the APAC Bioreactors Market profiled in the report are Sartorius AG, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, Danaher Corporation, Eppendorf AG, and significant Engineering, Procurement and Construction (EPC) players included in this report are Amec Foster Wheeler plc., Fluor Corporation, Jacobs Engineering Group Inc., M+W Group, PM Group, and Technip S.A.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com